[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"silent-cerebral-infarct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:silent-cerebral-infarct":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100491894","prevalence-of-attributable-etiology-and-modifiable-stroke-risk-factors-in-patients-with-covert-brain-infarctions-100491894",false,"NCT05685069","Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions","Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions (CBI-registry)","CBI-Registry","Inclusion Criteria:\n\n* Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either:\n\n  * DWI positive lesions: Focus of restricted diffusion (high DWI signal and low ADC value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for MS OR\n  * Cavitatory Lesions: ≥ 3 mm in size that follow CSF on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR\n  * T2W hyperintense\u002FT1W hypointense lesions: Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR present within cortical gray matter or deep gray matter nuclei OR a lesion that is new, compared with an MRI performed within 3 months OR T2W hyper\u002FT1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for MS or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning\n* Informed Consent as documented by signature by patient or legally authorized representative\n\nExclusion Criteria:\n\n* Projected life expectancy of less than 2 years,\n* Contraindication to MRI,\n* Patients with a history of symptoms compatible with an AIS\u002FTIA attributable to the lesion observed, covert neurological deficits are allowed,\n* Patient is already included in another clinical trial that will affect the objectives of this study,\n* Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his\u002Fher own wishes correspondingly,\n* Women who are pregnant or breast feeding or intention to become pregnant during the course of the study,\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Contraindications to any of the routine procedures, e.g. inability to obtain neurovascular ultrasound examination,\n* Known or suspected non-compliance, drug or alcohol abuse","ALL","16 Years",{"count":20,"type":21},230,"ESTIMATED","OBSERVATIONAL","The CBI registry is a prospective, interdisciplinary, multimodal observational registry of patients with covert brain infarction. Methods: A standardized workup in analogy to manifest ischemic stroke including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, laboratory work-up and risk factor assessment as well as noninvasive angiography of the cervical and intracranial arteries will be performed.",[25,26,27,28,29,30],"Silent Stroke","Silent Cerebral Infarct","Covert Brain Infarct","Covert Brain Infarction","Lacune","Silent Brain Infarction",[32,33,34],"Covert brain infarction","Covert cerebrovascular disease","Ischemic stroke","RECRUITING","2024-11-12",{"date":38,"type":39},"2024-11-14","ACTUAL",{"date":41,"type":39},"2019-03-01",{"date":43,"type":21},"2026-08-31",{"name":45,"class":46},"Insel Gruppe AG, University Hospital Bern","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100397008","incidence-of-silent-atrial-fibrillation-in-patients-with-clinically-silent-brain-ischemic-lesions-100397008","NCT04449523","Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions","Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions (SILENT2)","SILENT2","Inclusion Criteria:\n\n* Age\n\n  * ≥ 65 years\n  * ≥ 50 years AND one the following:\n\n    * NT-proBNP \\>400 pg\u002FmL\n    * Left atrial ventricular index \\>42 ml\u002Fm2 or left atrial diameter \\>46 mm\n    * Covert infarctions with cortical involvement in more than one vascular territory (left carotid territory, right carotid territory, vertebrobasilar territory)\n* Written informed Consent\n* Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either:\n\n  * Diffusion weighted imaging (DWI) positive lesions: Focus of restricted diffusion (high DWI signal and low apparent diffusion coefficient value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for multiple sclerosis OR\n  * Cavitatory Lesions: ≥ 3 mm in size that follow cerebro-spinal fluid on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR\n  * T2 weighted (T2W) hyperintense\u002FT1 weighted (T1W) hypointense lesions:\n\n    * Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR\n    * Present within cortical gray matter or deep gray matter nuclei OR\n    * A lesion that is new, compared with an MRI performed within 3 months OR\n    * T2W hyper\u002FT1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for multiple sclerosis or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning\n\nExclusion Criteria:\n\n* History of AF or atrial flutter\n* Patients with a history of symptoms compatible with an AIS, covert neurological deficits are allowed.\n* Cardiac implantable electronic devices (pacemaker, implantable cardiac defibrillator (ICD), implantable cardiac monitor (ICM))\n* Indication for cardiac implantable electronic device implantation (pacemaker, ICD, ICM)\n* History of or indication for major cardiac surgery or transcutaneous aortic valve implantation\n* Indication for permanent oral anticoagulation\n* Contraindication for permanent oral anticoagulation\n* Projected life expectancy of less than 2 years\n* Active intra- or extracranial high-grade malignancy\n* Patient is already included in another clinical trial that will affect the objectives of this study\n* Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his\u002Fher own wishes correspondingly\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Known or suspected non-compliance, drug or alcohol abuse","50 Years",{"count":57,"type":21},150,"Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and is associated with Silent Brain Infarction (SBI). However, the role of AF in the formation of lesions (SBIs) is less well established than its role in AIS and needs clarification.\n\nThe investigators hypothesize that continuous rhythm monitoring will yield a similar incidence of AF diagnosis in patients with SBI as compared to patients with cryptogenic AIS.\n\nThe primary objective is to assess the cumulative incidence of AF diagnosis at 24 months in patients with SBI.",[25,26,60],"Fibrillation",{"date":38,"type":39},{"date":63,"type":39},"2020-09-08",{"date":65,"type":21},"2029-12-31",{"name":45,"class":46},8]